Barclays PLC Eagle Pharmaceuticals, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 14,233 shares of EGRX stock, worth $16,652. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,233

Previous 15,043 5.38%

Holding current value

$16,652

Previous $56,000 87.5%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$0.35 - $3.56 $283 - $2,883	-810 Reduced 5.38%	14,233 $7,000
Q3 2024 Nov 15, 2024	SELL	$3.71 - $6.07 $15,084 - $24,680	-4,066 Reduced 21.28%	15,043 $56,000
Q2 2024 Aug 14, 2024	SELL	$3.34 - $5.6 $11,626 - $19,493	-3,481 Reduced 15.41%	19,109 $107,000
Q1 2024 May 15, 2024	SELL	$4.26 - $6.51 $29,790 - $45,524	-6,993 Reduced 23.64%	22,590 $119,000
Q4 2023 Feb 15, 2024	BUY	$4.63 - $15.21 $87,789 - $288,396	18,961 Added 178.51%	29,583 $155,000
Q3 2023 Nov 07, 2023	SELL	$15.21 - $22.88 $221,275 - $332,858	-14,548 Reduced 57.8%	10,622 $168,000
Q2 2023 Aug 03, 2023	BUY	$17.74 - $31.87 $347,703 - $624,652	19,600 Added 351.89%	25,170 $490,000
Q1 2023 May 04, 2023	SELL	$25.06 - $34.09 $722,354 - $982,644	-28,825 Reduced 83.81%	5,570 $158,000
Q4 2022 Feb 13, 2023	SELL	$24.98 - $39.77 $110,361 - $175,703	-4,418 Reduced 11.38%	34,395 $1.01 Million
Q3 2022 Nov 03, 2022	BUY	$26.42 - $47.12 $934,554 - $1.67 Million	35,373 Added 1028.28%	38,813 $1.03 Million
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $236,749 - $294,646	-5,738 Reduced 62.52%	3,440 $153,000
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $256,245 - $302,344	-5,748 Reduced 38.51%	9,178 $455,000
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $144,287 - $179,178	3,149 Added 26.74%	14,926 $759,000
Q3 2021 Nov 09, 2021	BUY	$43.79 - $55.78 $236,772 - $301,602	5,407 Added 84.88%	11,777 $657,000
Q2 2021 Aug 13, 2021	SELL	$36.86 - $44.5 $647,151 - $781,286	-17,557 Reduced 73.38%	6,370 $273,000
Q1 2021 May 13, 2021	SELL	$40.32 - $50.97 $64,713 - $81,806	-1,605 Reduced 6.29%	23,927 $998,000
Q4 2020 Feb 11, 2021	SELL	$41.72 - $51.34 $117,984 - $145,189	-2,828 Reduced 9.97%	25,532 $1.19 Million
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $541,010 - $749,405	14,614 Added 106.31%	28,360 $1.2 Million
Q2 2020 Aug 12, 2020	SELL	$43.24 - $55.02 $1.05 Million - $1.34 Million	-24,351 Reduced 63.92%	13,746 $659,000
Q1 2020 May 13, 2020	BUY	$34.37 - $60.07 $563,427 - $984,727	16,393 Added 75.53%	38,097 $1.75 Million
Q4 2019 Feb 10, 2020	SELL	$54.32 - $64.31 $752,114 - $890,436	-13,846 Reduced 38.95%	21,704 $1.3 Million
Q3 2019 Nov 14, 2019	BUY	$53.25 - $59.98 $254,588 - $286,764	4,781 Added 15.54%	35,550 $2.01 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $168,168 - $210,887	3,608 Added 13.28%	30,769 $1.71 Million
Q1 2019 May 15, 2019	BUY	$38.66 - $51.82 $232,810 - $312,060	6,022 Added 28.49%	27,161 $1.37 Million
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $255,240 - $470,791	-6,951 Reduced 24.75%	21,139 $852,000
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $1.15 Million - $1.45 Million	17,302 Added 160.38%	28,090 $1.95 Million
Q2 2018 Aug 14, 2018	BUY	$51.25 - $76.62 $319,902 - $478,262	6,242 Added 137.31%	10,788 $817,000
Q1 2018 May 15, 2018	SELL	$52.16 - $66.86 $716,521 - $918,455	-13,737 Reduced 75.14%	4,546 $238,000
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $856,889 - $1.05 Million	17,276 Added 1715.59%	18,283 $976,000
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $46,946 - $60,782	1,007	1,007 $60,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

3.82M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $15.2M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account